556 related articles for article (PubMed ID: 19801990)
1. Development of universal antidotes to control aptamer activity.
Oney S; Lam RT; Bompiani KM; Blake CM; Quick G; Heidel JD; Liu JY; Mack BC; Davis ME; Leong KW; Sullenger BA
Nat Med; 2009 Oct; 15(10):1224-8. PubMed ID: 19801990
[TBL] [Abstract][Full Text] [Related]
2. Antidote control of aptamer therapeutics: the road to a safer class of drug agents.
Bompiani KM; Woodruff RS; Becker RC; Nimjee SM; Sullenger BA
Curr Pharm Biotechnol; 2012 Aug; 13(10):1924-34. PubMed ID: 22352726
[TBL] [Abstract][Full Text] [Related]
3. The potential of aptamers as anticoagulants.
Nimjee SM; Rusconi CP; Harrington RA; Sullenger BA
Trends Cardiovasc Med; 2005 Jan; 15(1):41-5. PubMed ID: 15795162
[TBL] [Abstract][Full Text] [Related]
4. Aptamers: the emerging class of future anticoagulation for vascular disease.
Kuliczkowski W; Floyd J; Malinin A; Serebruany V
Expert Rev Cardiovasc Ther; 2010 Apr; 8(4):503-7. PubMed ID: 20397824
[TBL] [Abstract][Full Text] [Related]
5. RNA aptamers as reversible antagonists of coagulation factor IXa.
Rusconi CP; Scardino E; Layzer J; Pitoc GA; Ortel TL; Monroe D; Sullenger BA
Nature; 2002 Sep; 419(6902):90-4. PubMed ID: 12214238
[TBL] [Abstract][Full Text] [Related]
6. Targeting Two Coagulation Cascade Proteases with a Bivalent Aptamer Yields a Potent and Antidote-Controllable Anticoagulant.
Soule EE; Bompiani KM; Woodruff RS; Sullenger BA
Nucleic Acid Ther; 2016 Feb; 26(1):1-9. PubMed ID: 26584417
[TBL] [Abstract][Full Text] [Related]
7. Polyvalent nucleic acid aptamers and modulation of their activity: a focus on the thrombin binding aptamer.
Musumeci D; Montesarchio D
Pharmacol Ther; 2012 Nov; 136(2):202-15. PubMed ID: 22850531
[TBL] [Abstract][Full Text] [Related]
8. First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity.
Dyke CK; Steinhubl SR; Kleiman NS; Cannon RO; Aberle LG; Lin M; Myles SK; Melloni C; Harrington RA; Alexander JH; Becker RC; Rusconi CP
Circulation; 2006 Dec; 114(23):2490-7. PubMed ID: 17101847
[TBL] [Abstract][Full Text] [Related]
9. Antidote-mediated control of an anticoagulant aptamer in vivo.
Rusconi CP; Roberts JD; Pitoc GA; Nimjee SM; White RR; Quick G; Scardino E; Fay WP; Sullenger BA
Nat Biotechnol; 2004 Nov; 22(11):1423-8. PubMed ID: 15502817
[TBL] [Abstract][Full Text] [Related]
10. Rapidly regulating platelet activity in vivo with an antidote controlled platelet inhibitor.
Nimjee SM; Lohrmann JD; Wang H; Snyder DJ; Cummings TJ; Becker RC; Oney S; Sullenger BA
Mol Ther; 2012 Feb; 20(2):391-7. PubMed ID: 22086230
[TBL] [Abstract][Full Text] [Related]
11. Applications and future of aptamers that achieve rapid-onset anticoagulation.
Yu H; Frederiksen J; Sullenger BA
RNA; 2023 Apr; 29(4):455-462. PubMed ID: 36697262
[TBL] [Abstract][Full Text] [Related]
12. Nucleic acid therapeutics: a focus on the development of aptamers.
Jain S; Kaur J; Prasad S; Roy I
Expert Opin Drug Discov; 2021 Mar; 16(3):255-274. PubMed ID: 32990095
[TBL] [Abstract][Full Text] [Related]
13. Biologics: The quest for a universal antidote.
Flight MH
Nat Rev Drug Discov; 2009 Dec; 8(12):934. PubMed ID: 19967801
[No Abstract] [Full Text] [Related]
14. An anticoagulant with light-triggered antidote activity.
Heckel A; Buff MC; Raddatz MS; Müller J; Pötzsch B; Mayer G
Angew Chem Int Ed Engl; 2006 Oct; 45(40):6748-50. PubMed ID: 16983715
[No Abstract] [Full Text] [Related]
15. Rapid Complexation of Aptamers by Their Specific Antidotes.
Stoll H; Steinle H; Wilhelm N; Hann L; Kunnakattu SJ; Narita M; Schlensak C; Wendel HP; Avci-Adali M
Molecules; 2017 Jun; 22(6):. PubMed ID: 28594360
[TBL] [Abstract][Full Text] [Related]
16. A potent anti-coagulant RNA aptamer inhibits blood coagulation by specifically blocking the extrinsic clotting pathway.
Gopinath SC; Shikamoto Y; Mizuno H; Kumar PK
Thromb Haemost; 2006 May; 95(5):767-71. PubMed ID: 16676065
[TBL] [Abstract][Full Text] [Related]
17. Aptamers: an emerging class of therapeutics.
Nimjee SM; Rusconi CP; Sullenger BA
Annu Rev Med; 2005; 56():555-83. PubMed ID: 15660527
[TBL] [Abstract][Full Text] [Related]
18. Antidote-controlled DNA aptamer modulates human factor IXa activity.
Fang L; Jin J; Zhang Z; Yu S; Tian C; Luo F; Long M; Zuo H; Lou S
Bioorg Chem; 2024 Jul; 148():107463. PubMed ID: 38776649
[TBL] [Abstract][Full Text] [Related]
19. In-vitro evaluation of anti-factor IXa aptamer on thrombin generation, clotting time, and viscoelastometry.
Tanaka KA; Szlam F; Rusconi CP; Levy JH
Thromb Haemost; 2009 May; 101(5):827-33. PubMed ID: 19404534
[TBL] [Abstract][Full Text] [Related]
20. A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery.
Nimjee SM; Keys JR; Pitoc GA; Quick G; Rusconi CP; Sullenger BA
Mol Ther; 2006 Sep; 14(3):408-15. PubMed ID: 16765093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
